Cosmo Pharmaceuticals N.V (C43) - Total Liabilities

Latest as of December 2025: €123.46 Million EUR ≈ $144.34 Million USD

Based on the latest financial reports, Cosmo Pharmaceuticals N.V (C43) has total liabilities worth €123.46 Million EUR (≈ $144.34 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check C43 financial resilience to evaluate the company's liquid asset resilience ratio.

Cosmo Pharmaceuticals N.V - Total Liabilities Trend (2016–2025)

This chart illustrates how Cosmo Pharmaceuticals N.V's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V Competitors by Total Liabilities

The table below lists competitors of Cosmo Pharmaceuticals N.V ranked by their total liabilities.

Company	Country	Total Liabilities
Verve Therapeutics Inc NASDAQ:VERV	USA	$140.65 Million
JiangSu Jin Tong Ling Fluid Mach SHE:300091	China	CN¥543.06 Million
Insigma SHG:600797	China	CN¥1.81 Billion
Shaanxi Fenghuo Electronics Co Ltd SHE:000561	China	CN¥3.82 Billion
Bafang Electric Suzhou Co Ltd SHG:603489	China	CN¥509.29 Million
Tejas Networks Limited NSE:TEJASNET	India	Rs65.60 Billion
CBL & Associates Properties Inc NYSE:CBL	USA	$2.39 Billion
Yotrio Group Co Ltd SHE:002489	China	CN¥2.81 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Cosmo Pharmaceuticals N.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Cosmo Pharmaceuticals N.V to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	7.18	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.26	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.20	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Cosmo Pharmaceuticals N.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Cosmo Pharmaceuticals N.V (2016–2025)

The table below shows the annual total liabilities of Cosmo Pharmaceuticals N.V from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€123.46 Million ≈ $144.34 Million	-12.86%
2024-12-31	€141.68 Million ≈ $165.64 Million	+15.73%
2023-12-31	€122.42 Million ≈ $143.12 Million	-58.61%
2022-12-31	€295.80 Million ≈ $345.83 Million	+1.00%
2021-12-31	€292.88 Million ≈ $342.41 Million	+49.40%
2020-12-31	€196.04 Million ≈ $229.19 Million	+2.41%
2019-12-31	€191.43 Million ≈ $223.80 Million	+5.86%
2018-12-31	€180.83 Million ≈ $211.41 Million	+549.14%
2017-12-31	€27.86 Million ≈ $32.57 Million	-0.21%
2016-12-31	€27.92 Million ≈ $32.64 Million	--

About Cosmo Pharmaceuticals N.V

F:C43 Germany Drug Manufacturers - General

Market Cap

$1.11 Billion

€950.63 Million EUR

Market Cap Rank

#8977 Global

#1150 in Germany

Share Price

€55.30

Change (1 day)

+0.18%

52-Week Range

€54.90 - €139.00

All Time High

€153.25